Homocystinuria due to homozygous cystathionine tl-synthase deficiency is an inborn error of metabolism characterized by a high incidence of thrombosis and premature atherosclerosis. We evaluated TXA2 biosynthesis in vivo and several in vitro tests of platelet function in 11 homocystinuric patients and 12 healthy controls. In vitro, patients' platelet aggregation was within control values as were TXB2 formation, fibrinogen binding, and ATP secretion in response to thrombin. In contrast, the urinary excretion of 1 1-dehydro-TXB2, a major enzymatic derivative of TXA2, was > 2 SD of controls in all patients (1,724±828 pg/mg creatinine, mean±SD, in patients vs. 345±136 in controls, P < 0.001). The administration to four patients of low-dose aspirin (50 mg/d for 1 wk) reduced metabolite excretion by > 80%. The recovery of 11-dehydro-TXB2 excretion over the 10 d that followed aspirin cessation occurred with a pattern consistent with the entry into the circulation of platelets with intact cyclooxygenase activity. Prolonged partial reduction in the abnormally high excretion of both 1i-dehydro-TXB2 and 2,3-dinor-TXB2, was also observed in seven patients who ingested 500 mg daily for 3 wk of the antioxidant drug probucol. These results provide evidence for enhanced thromboxane biosynthesis in homocystinuria and for its partial dependence on probucol-sensitive mechanisms. Furthermore, the elevated TXA2 formation in homocystinuria is likely to reflect, at least in part, in vivo platelet activation. (J. Clin. Invest.
Homocystinuria due to cystathionine f-synthase deficiency (CBSD)' is a recessively inherited error of metabolism strongly associated with premature atherosclerosis and arterial and venous thrombosis (1) (2) (3) (4) . Some hemostatic factors that may contribute to this tendency have been investigated in a large series of studies (5) (6) (7) (8) (9) (10) (11) (12) (13) . Plasma coagulation factor VII, platelet survival, and antithrombin III activity have been reported to be abnormal (5) (6) (7) (8) (9) (10) . However, these claims have been challenged (1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Biochemical measurements of urinary TX metabolites and clinical trials with aspirin indicate that enhanced biosynthesis of TXA2 by platelets is an important contributor to the risk of thrombosis associated with several cardiovascular risk factors ( 14) . Abnormally high levels of 2,3-dinor-TXB2, an enzymatic derivative of TXA2, have been reported in the urines of a CBSD patient (15) . Therefore, we investigated TXA2 biosynthesis and its inhibition by low-dose aspirin, as reflected by the urinary excretion of its major metabolites, 1 1-dehydro-TXB2 and 2,3-dinor TXB2, in a larger group ofCBSD patients and controls with the aim of establishing the prevalence of this biochemical abnormality and its cellular source.
Hemostatic abnormalities involving antithrombin III, fibrinogen, plasminogen activator inhibitor-1, or tissue plasminogen activator have been reported in other clinical settings characterized by a thrombotic tendency (16) (17) (18) . These abnormalities are currently thought to be associated with high circulating levels of thrombin. In addition to its role in the conversion of fibrinogen to fibrin, thrombin is a potent inducer of platelet TXA2 biosynthesis. Low levels ofantithrombin III, the major plasma inhibitor of thrombin, have been reported in CBSD patients (6) (7) (8) . To examine the possibility that the enhanced excretion of TXA2 metabolites in homocystinuria might be due to high circulating levels of thrombin, we measured several hemostatic variables that reflect a hypercoagulable state. The administration ofprobucol has been reported to prevent the increased TXA2 biosynthesis ofcholesterol-fed rats ( 19) . This has been suggested to depend on probucol-sensitive oxidative mechanisms ( 19) . To gain insight into the mechanisms responsible for enhanced thromboxane biosynthesis in homocystinuria, the effects of a short-term course of probucol therapy on metabolite excretion were assessed in seven CBSD patients. Our results provide preliminary evidence that probucol may partially reduce the enhanced in vivo biosynthesis of TXA2 in homocystinuria.
Methods
Subjects. 11 CBSD patients (5 females, 6 males, yr) belonging to 8 unrelated families and 17 healthy control subjects (7 females, 10 males, 14-44 yr) were studied. None of the control subjects had a history of disease known to alter platelet function. All patients fulfilled the criteria (20) for the diagnosis of the homozygous form of CBSD in that all exhibited ectopia lentis, homocystinuria, and abnormally high plasma levels of methionine and homocystine with low or undetectable levels of cystine (21) .
All but one (see Table I ) were responsive to pyridoxine and had been on pyridoxine treatment (600-900 mg/d) from the time of the diagnosis. The pyridoxine-unresponsive subject was on 8 g/d betaine. Skin fibroblast cultures (22) showed an abnormally low activity (< 1% of controls) of cystathionine f-synthase in four patients. The other seven patients were not evaluated. For all the data reported in the results section, no statistically significant differences were found between the four patients tested and the other seven patients. All (24, 25) . This assay has been validated for the measurement of metabolite levels in human urine by comparison with negative ion-chemical ionization gas-chromatography/mass spectrometry (24) . Immunoreactive 2,3-dinor-TXB2 was measured by a previously validated RIA (26) after separating the metabolite from TXB2. This was achieved by subjecting the eluates prepared for 1 l-dehydro-TXB2 measurements to reverse-phase high pressure liquid chromatography (solvent system, acetonitrile/water/acetic acid [27:73:0.18]; flowrate, 0.5 ml/min). Urine creatinine was determined according to the manufacturer's recommendations (Behring Testomar-Creatinina Combipack, Scoppito, Italy).
Studies on platelets and fibrinolysis. Aggregation of platelets in platelet-rich plasma, TXB2 synthesis, and ATP secretion in response to 1 or 5 U/ml thrombin, preparation of suspensions ofwashed platelets, purification and labeling of human fibrinogen, thrombin-dependent fibrinogen binding, and analysis ofthe binding data were performed as previously described (23) . For studies on the sensitivity of platelets to aggregating agents, the AC50 was calculated. This was defined as the concentration of an agonist that produced 50% light transmittance within 3 min after addition to the platelet suspension. For binding studies, hirudin was added in microliter volumes at a final concentration of0.1 U/ml to unstirred platelet suspensions to prevent clotting of fibrinogen by thrombin (0.1 U/ml). Fibrinolytic activity in the plasma euglobulin fraction was determined before and after 10 min of venous stasis and expressed in tissue plasminogen activator equivalent units with reference to data obtained using purified melanoma tissue plasminogen activator. Tissue plasminogen activator-and inhibitor-1-related antigens were measured by an ELISA method according to the manufacturer's recommendations, whereas the biological activity of the plasminogen activator inhibitor was studied by an amidolytic assay (27) .
Other assays. The total cholesterol, triglyceride, and plasma glucose levels were measured according to standard procedures (27) .
Clinical protocols. Informed consent was obtained from all patients and volunteers after approval ofthe protocols by the Human Investigation Committee, and the studies were carried out according to the principles expressed in the Declaration ofHelsinki. Because aspirin is present in so many over-the-counter preparations, all subjects were asked to avoid cold remedies during the study. Neither patients nor controls had taken any medication known to interfere with arachidonate metabolism or platelet function for > 1 wk before blood sampling. On every occasion and for each subject, after 12-15 h of overnight fasting, 45 ml of blood was collected at 9-9.30 a.m., from the antecubital vein, via a 19-gauge scalp vein needle, into a sterile plastic tube containing 5 ml of sterile 3.8% trisodium citrate, and was immediately processed.
In the first phase of the study, a comparison of 1 1-dehydro-TXB2 excretion and in vitro platelet function between CBSD patients and controls was performed. For these determinations, blood samples collected in the morning as reported above, and the urines, collected during the overnight fasting, were used. The urines were immediately frozen and kept at -70°C until extracted. Nine CBSD patients were studied after being on long-term treatment with pyridoxine (Table I) . Two newly diagnosed patients were studied both before and 4-12 wk after starting pyridoxine. To further investigate the potential effect of this therapy on 1 1-dehydro-TXB2 excretion, three healthy volunteers (all males, aged 26-30 yr) were instructed to take pyridoxine 900 mg/d for 4 wk and urines were collected twice before treatment and at 1, 2, 3, and 4 wk on treatment. Results from the first phase of the study indicated an abnormally high 1 -dehydro-TXB2 excretion and a normal in In the last phase ofthe study, 500-mg tablets of probucol (Lurselle; Lepetit, Milan, Italy) were administered daily for 3 wk to 7 patients, and 12-h urines were collected before, on the last day oftreatment, and 3 wk later. To determine whether the inhibitory effect of probucol on I I-dehydro-TXB2 excretion was due to impaired TXA2 biosynthesis or to a shift in its metabolic disposition from the 1 1-hydroxydehydrogenase pathway (28), the urinary excretion of the metabolite generated through the #-oxidation pathway, 2,3-dinor-TXB2, was also measured.
To interpret changes in 1 l-dehydro-TXB2 excretion associated with probucol administration to CBSD patients, 5 healthy subjects were instructed to take 500 mg probucol daily for 3 wk, and 12-h urines were collected before; at the end of the 1st, 2nd, and 3rd wk of treatment; and during the following 3 
Results
Studies on the urinary excretion of1J-dehydro-TXB2. In control subjects the urinary excretion of 1 l-dehydro-TXB2 averaged 345± 136 pg/mg creatinine (range, 138-606). CBSD patients had significantly (P < 0.001) higher metabolite excretion: 1,724±828 pg/mg creatinine. All patients had metabolite excretion > 2 SD above the control mean. Enhanced thromboxane biosynthesis was unrelated to cardiovascular risk factors and independent ofdetectable atherosclerotic vascular disease (Table II) . 1 1-dehydro-TXB2 measurements were highly binding were comparable in CBSD patients and controls. Likewise, the coagulation and fibrinolytic factors analyzed were all within control values. These values are similar to those previously reported for normal subjects (16) (17) (18) . No correlation was found between any of the parameters reported in this section and 1 1-dehydro-TXB2 excretion in CBSD.
Effect ofprobucol on I J-dehydro-TXB2 and 2,3-dinor-TXB2
excretion. To gain insight into the mechanism(s) responsible for enhanced TXA2 biosynthesis in CBSD, the antioxidant drug probucol was given daily for 21 d to seven patients (S.R., S.S., D.A.M., D.A., M.A., M.L., and T.G.). The rate of TX metabolite excretion at baseline averaged 1,647±981 pg/mg creatinine. At the end of probucol treatment (Fig. 2, top) , 1 1-dehydro-TXB2 excretion was reduced by -40% (P < 0.01 vs. preprobucol values). Plasma cholesterol was also significantly (P < 0.05) reduced from 154±12 to 131±9 mg/dl. 3 wk after withdrawing drug therapy, at a time when plasma cholesterol was comparable to baseline values (140±35, P > 0.05), 1 1-dehydro-TXB2 excretion was still significantly reduced (P < 0.005 vs. preprobucol data). We interpret this prolonged inhibition to reflect the very long half-life ofthe drug (34) . The response to probucol showed a large interindividual variation in that the patients experienced a 30-70% reduction in metabolite excretion. The effect ofprobucol on TXA2 biosynthesis was further analyzed by measuring the urinary excretion ofthe metabolite generated through the f-oxidation pathway, 2,3-dinor-TXB2 (28). At baseline, CBSD patients had significantly (P < 0.005) higher 2,3-dinor-TXB2 excretion than control subjects (697±538 pg/mg creatinine in CBSD, range: 351-1,888, vs. 214±1 1 pg/ mg creatinine in controls, range: 63-345). Six of the seven patients had urinary metabolite excretion > 2 SD above the control mean. 3 wk after withdrawing probucol treatment (Fig. 2, bottom) , 2,3-dinor-TXB2 excretion was reduced to 355±231 (P < 0.005 vs. preprobucol data). As for 1 1-dehydro-TXB2, the effect of probucol on 2,3-dinor-TXB2 excretion showed a large interindividual variability in that the patients exhibited a 30-80% reduction in metabolite excretion. When the individual data from samples obtained 3 wk after withdrawing probucol therapy were analyzed, a statistically significant correlation (r = 0.76, P < 0.05) was found between the reduction in urinary excretion of 1 1-dehydro-TXB2 and that of 2,3-dinor-TXB2 (Fig. 3 ).
At variance with the effect on TXB2 metabolite excretion observed in CBSD, the same regimen ofprobucol did not affect 1 l-dehydro-TXB2 excretion in five control subjects to any statistically significant extent. Thus, metabolite excretion averaged 360±115 pg/mg creatinine at baseline; 368±86, 320±116, and 392+124 at the end of the 1st, 2nd, and 3rd wk of probucol administration; respectively, and remained stable at 388±108, 373±94, and 401±115 pg/mg creatinine over the following 3 wk after drug withdrawal.
Discussion
In its homozygous form, homocystinuria due to cystathionine f3-synthase deficiency is characterized by multiple biochemical abnormalities, mental retardation, ectopia lentis, osteoporosis, premature atherosclerosis, and venous and arterial thrombosis. Although the mechanism is largely unknown, the administration ofpharmacological doses ofvitamin B6 (100-1,000 mg/d) appears to correct, at least in part, most clinical symptoms and biochemical abnormalities in about halfofthe patients. In contrast, the problem of premature atherosclerosis and its thrombotic complications continues to be an important one in the management of CBSD (1) (2) (3) (4) . At variance with the homozygous state, heterozygosity for homocystinuria is a rather common entity ( 1 of 100-200 live births) and recent reports (3, 4, 35) indicate that the homocystinuric trait is associated with a similar tendency to atherosclerosis and its thrombotic complications. The pathophysiological and clinical implications of this disease, as well as the observation that abnormalities in platelet arachidonate metabolism are often present in patients at risk for thrombosis ( 14) , prompted us to study thromboxane biosynthesis in CBSD. The urinary excretion of 1 1-dehydro-TXB2, a major enzymatic derivative of TXA2, was approximately fivefold higher in CBSD patients than controls. This alteration was independent of the presence of other cardiovascular risk factors or atherosclerotic vascular disease. Moreover, the finding of similarly increased excretion of 2,3-dinor-TXB2 strongly argues for these biochemical changes reflecting enhanced biosynthesis ofTXA2 rather than altered metabolic disposition in the setting of CBSD.
Urinary eicosanoid metabolites do not reflect a specific site of eicosanoid biosynthesis ( 14) . In an attempt to characterize the cellular source of the abnormally high TXA2 biosynthesis in homocystinuria, we administered aspirin, 50 mg daily for 1 wk, and evaluated the pattern of inhibition and recovery of 1 l-dehydro-TXB2 excretion in four patients. This regimen is known to impair platelet TXA2 synthesis in a relatively selective cumulative fashion (30, 31 ) . The finding of 82-84% suppression of TX metabolite excretion upon repeated daily dosing with 50 mg of aspirin suggests that this was achieved through a process of cumulative inhibition, inasmuch as a single administration of the same dose only produces 50% inhibition of platelet cyclooxygenase activity (30) . A pattern of cumulative inhibition is consistent with the rate of enzyme turn over or cell renewal being longer than the 24-h dosing interval. Both such profound suppression and the incomplete recovery of TX metabolite excretion at 4 and 7 d after aspirin withdrawal are compatible with this pattern, reflecting cumulative acetylation by aspirin of platelet prostoglandin/H-synthase and the slow entry of new platelets with intact enzyme into the systemic circulation, respectively. However, these considerations do not exclude the possibility that extraplatelet sources (e.g., macrophages infiltrating atherosclerotic lesions) ofTXA2 biosynthesis may contribute, at least in part, to enhanced metabolite excretion in the setting of homozygous homocystinuria.
In type II diabetes mellitus, enhanced TX biosynthesis is associated with increased in vitro sensitivity of platelets to aggregating agents (36) . Therefore, we examined platelet function ex vivo. The data obtained indicate that platelets from CBSD patients aggregate, secrete ATP, form TXB2, and bind fibrinogen in a fashion indistinguishable from controls. Changes in the plasma levels of some hemostatic variables are thought to be associated with high circulating levels of thrombin (15) (16) (17) (18) . To 19) have shown that the antioxidant drug probucol prevented the hemodynamic abnormalities as well as the increased TXA2 biosynthesis in rats on short-term cholesterol feeding. To gain insight into the mechanism(s) responsible for enhanced TXA2 biosynthesis in homocystinuria, we evaluated the effects of a 3-wk administration of probucol on the urinary excretion of l1-dehydro-TXB2 and 2,3-dinor-TXB2. Both were partially, though persistently, reduced by this treatment, suggesting an effect ofprobucol on TXA2 biosynthesis. This is unlikely to reflect a direct inhibitory effect ofprobucol on platelet function or enzymes involved in arachidonate metabolism, inasmuch as 1 l-dehydro-TXB2 excretion was unaltered in control subjects exposed to the same drug regimen. The study of Kaplan et al.. ( 19) showed that although the administration of probucol did not affect the feeding-related rise in low density lipoproteins, and only partially prevented that of total cholesterol, it entirely corrected the increased TXB2 excretion of cholesterol-fed rats. Cholesterol levels were entirely normal in our patients, and no correlation was found between baseline levels of plasma cholesterol and urinary 1 -dehydro-TXB2 (Table II) . 3 wk after withdrawing probucol, the urinary excretion of TX metabolites was still significantly reduced, at a time when plasma cholesterol was not significantly different from preprobucol values.
Thus, although elevated levels ofplasma cholesterol may be causally related to elevated 1 l-dehydro-TXB2 excretion in type IIa hypercholesterolemia (37) , the rather trivial (9-15%) reduction in blood cholesterol vis-a-vis the 40-60% drop in TX metabolite excretion, the lack of correlation between the two, and the time-dependent dissociation of the observed changes during and after probucol treatment, all argue against the involvement ofcholesterol in the enhanced TXA2 biosynthesis in homocystinuria as well as in its partial correction by probucol. The production of oxidized low density lipoproteins is facilitated by thiol compounds, including homocysteine (38, 39) . Oxidized low density lipoproteins induce platelet activation and TX formation (40) . In vitro incubation of platelet-rich plasma with homocysteine increases the formation ofTXB2 by platelets (41 ) . In vitro, probucol prevents the oxidative modification oflow density lipoproteins (34, 42) . Thus, in spite ofthe limitations inherent to a short-term, open study, inhibition by probucol of the elevated TXA2 biosynthesis is consistent with the possibility that in vivo oxidized low density lipoproteins mediate, at least in part, the increased platelet arachidonate metabolism in homocystinuria.
It has also been suggested that probucol's antiatherosclerotic activity may be related to inhibition of interleukin 1 secretion by macrophages (43, 44) . Thus, an effect of probucol on extraplatelet sources of TXA2 biosynthesis, independent of its antioxidant activity, cannot be excluded by our findings. The possibility of an important role of macrophages would be consistent with unaltered platelet TXA2 production in vitro and enhanced TXA2 biosynthesis in vivo, as detected in our CBSD patients. The use of MDL 29,311, which is an analogue of probucol that does not lower cholesterol but does have full antioxidant activity (45) , or other antioxidant interventions might help to clarify these mechanistic uncertainties.
These results provide biochemical evidence of enhanced TXA2 biosynthesis in homocystinuria and of its partial dependence on probucol-sensitive mechanisms. Our data also suggest that this abnormality may reflect the activation ofplatelets and other cells with comparable aspirin sensitivity in response to stimuli operating in vivo, the nature of which remains to be determined. We believe that information from these studies allows for a better understanding ofthe tendency to thrombosis in homocystinuria and helps identify the mechanism(s) of homocysteinemia as a risk factor for atherosclerotic cardiovascular disease. Finally, our results provide a rationale for testing the efficacy and safety of low-dose aspirin in this setting.
